How are Indian generics impacting the global weight-loss drug market?

Indian generics firms are launching cheaper versions of popular weight-loss drugs like Mounjaro and Wegovy, aiming to undercut global prices by up to 95% and make these treatments more accessible worldwide.

What is the current state of the weight-loss drug market in India?

The Indian weight-loss drug market is projected to reach $1 billion in the next few years, driven by surging demand as two major weight-loss medications became legally available in the country earlier this year.

How are Indian companies leveraging their unique advantages to compete in the global weight-loss drug market?

Indian firms are developing weight-loss solutions tailored to the country's large obese population, high diabetes rates, and genetic predispositions. They are also working on oral alternatives to injectable drugs to overcome logistical challenges.

Home / Health / Indian Generics Aim to Slim Down Global Weight-Loss Drug Prices

Indian Generics Aim to Slim Down Global Weight-Loss Drug Prices

31 Jul

•

Summary

Demand for weight-loss drugs surging in India, market could reach $1B
Indian generics firms racing to launch cheaper versions of global blockbusters
Potential for Indian-made drugs to disrupt $150B global weight-loss market

Indian Generics Aim to Slim Down Global Weight-Loss Drug Prices

As of July 2025, the Indian market for weight-loss drugs is experiencing a surge in demand. Two major weight-loss medications, Mounjaro and Wegovy, became legally available in India earlier this year, sparking a rapid rise in consumption. Experts predict India's weight-loss drug market could soon grow to $1 billion, a significant portion of the projected $150 billion global market over the next decade.

Indian pharmaceutical companies are poised to capitalize on this opportunity. Generic drug makers like Biocon and Sun Pharma are already offering cheaper versions of existing weight-loss treatments, and industry giant Cipla plans to produce knock-offs of the popular semaglutide drug when its patent expires in India next year. With the ability to undercut global prices by up to 95%, these Indian generics could make weight-loss medications far more accessible worldwide.

Factors like India's large obese population, high prevalence of diabetes, and unique genetic predispositions give Indian firms a strategic advantage in developing tailored weight-loss solutions. Additionally, the logistical challenges of distributing injectable drugs in India's hot climate have spurred the development of oral alternatives that could rival injectables. Whoever can bring an effective, affordable weight-loss pill to market will likely dominate not just the Indian, but the global market as well.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.